We fetch to your notice a new website where you can buy kamagra jelly australia at a low cost with fast delivery to Australia.

Richpharmaceuticals.com


September 6, 2013

Rich Pharmaceuticals Appoints David Chou, Ph.D to CMC Director and Board Member

Beverly Hills, Calif., September 6, 2013 (NEWSWIRE) – RICH PHARMACEUTICALS, INC. (OTC BB: RCHA), a leader in
the discovery and development of therapeutic treatments for acute myelogenous leukemia and stroke, today announced
David Chou, Ph.D. has joined the company as CMC Director and appointed to the Board by Mr. Chang, CEO Chairman of
the Board of Rich Pharmaceuticals, Inc., The sole director expanded the number of Board of Directors to two (2) members
and appointed David Chou, Ph.D., as a director to fill the vacancy. Mr. Chou is a pharmaceutical development expert with
more than 25 years of experience and he has led numerous development projects from pre-clinical evaluation stage to
product commercialization. Prior to joining Rich Pharmaceuticals, Mr. Chou was the Chief Product Development Officer at
Biosuccess Biotech where he led the product development and manufacturing activities for various indications. Before his
career with Biosuccess Biotech, Mr. Chou was the Head of CMC (a Vice President level position) at SBIO, Inc. from 2010
to 2012. While at SBIO, he managed the technical development of 4 clinical stage products and made significant
contributions to the success of product out-licensing deals with a total value of more than $500 million. From 1998 to 2010,
Mr. Chou held director level positions in pharmaceutical development fields at various biopharmaceutical companies
including Neurobiological Technologies, PharmaEngine, Oculex and SUGEN and his development portfolios included
Sutent® currently marketed by Pfizer and OZURDEX® marketed by Allergan. Prior to his biotech career, Mr. Chou held
various management positions at Hoffmann La-Roche for more than 12 years. At Roche, his development team contributed
and submitted more than 20 INDs and 6 full NDAs including marketed products such as Xeloda® (Capecitabine), Xenical®
(Orlistat) and Hivid® (Zalcitabine). Mr. Chou received a Ph.D. degree in Chemistry from the City University of New York. In
connection with his appointment, the Company granted Mr. Chou options to purchase up to 9,600 shares of Company
common stock at an exercise price of $8.00 per share, 50% of which are vested on the date of grant, and 50% of which will
vest monthly over 24 months of continued services to the Company. The Board of Directors of the Company also approved
entering into a one year employment agreement with Mr. Chou for his appointment as the CMC Director of the Company
with an annual salary of $180,000, to commence effective upon the Company and Mr. Chou entering into the employment
agreement
About RICH
Rich Pharmaceuticals is a biopharmaceutical company focused on the development of its lead product, TPA (12-O-
tetradecanoylphorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients, and the
reversal of physical disabilities resulting from stroke. The basis for the interest of the Company to pursue clinical
development of TPA in these and possibly other indications is the result of the work of two scientists, Prof. Richard Chang
and Prof. Zhang Tao Han. Both have conducted research on TPA for many years and have become experts in the
characteristics of this molecule. Their findings form the scientific basis for the clinical use of TPA. .More detailed
information can be found at www.RichPharmaceuticals.com.
Forward-Looking Statements
Certain statements contained in this press release including, but not limited to, statements related to anticipated timing of
completion of clinical trials, the successful outcome of clinical trials, regulatory approval of unapproved product
candidates, anticipated commercial success of currently unapproved products, or that otherwise relate to future periods
are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate, and actual
results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for
companies engaged in the development of new products in a regulated market. Potential risks to RICH meeting these
expectations are described in more detail in RICH's most recent filing on Form 10-K and in other SEC filings. Consider
such risks carefully when considering RICH's prospects. Any forward-looking statement in this press release represents
RICH's views only as of the date of this press release and should not be relied upon as representing its views as of any
subsequent date. RICH PHARMACEUTICALS, INC. disclaims any obligation to update any forward-looking statement,
except as required by applicable law.
Investor Contact:
Joseph Huffman, Finance Director
424-230-7001 Ext. 110
[email protected]
Source: RICH Pharmaceuticals, Inc.

Source: http://www.richpharmaceuticals.com/wp-content/uploads/2013/09/David-Chou-Press-Release-9-6-13.pdf

Microsoft word - wyeth.docx

RESEARCH Wyeth Ltd. DEFENSIVE BET Key Indicators as on 09/05/2012 SOURCE:CMIE Investment highlights: Closing Price (Rs.) - TTM EPS (Rs.) - TTM BV per Share (Rs.) - TTM Mkt Cap (Rs. Crore) - TTM 1,943.59 Beta - TTM Mkt Cap/Sales (March -11) Mkt Cap/PBIDTA (March -11) Mkt Cap/PBDT (March -11) Mkt Cap/PAT (Mar

caiinsurancesolutions.com

The following is a list of commonly prescribed drugs covered under the EmblemHealth pharmacy program. To obtain the complete formulary, please visit www.emblemhealth.com . The list is not all inclusive and does not guarantee coverage. We encourage you to ask your doctor to prescribe generic drugs whenever appropriate. PLEASE NOTE: Drugs listed on this document may become non-Preferred if a g

Copyright © 2010-2014 Medical Science